Formulary & Prescribing Guidelines – Mental Health

The Trust’s Formulary and Prescribing Guidelines relates to those medicines used for the treatment of mental health conditions. Patients who are admitted for treatment of a mental health condition and also require medicines for the treatment of physical health condition will usually continue to receive the treatment they were previously being prescribed unless there are clinical reasons why this needs to be changed.

The Trust’s Mental Health and Learning Disabilities Medicines Management Committee aids prescribers by evaluating the evidence for new and existing drugs, and making recommendations on therapy based on clinical and cost-effectiveness grounds. Where appropriate, restrictions on the use of particular drugs may be recommended. The Formulary and Prescribing Guidelines contains information on those drugs approved for use within the mental health services of South Essex Partnership NHS Foundation Trust, together with supporting information to aid clinical decision making.

The formulary is not intended to supersede positive NICE Technology Appraisals (TAs). Most NICE TA approved drugs will not be appropriate for initiation within mental health services and so not all will be specifically mentioned. Clinicians can and should prescribe medicines, for the treatment of a mental health condition, approved within a NICE TA where patients meet the clinical criteria set out in the guidance and it is the most appropriate treatment option in the clinical judgement of the treating clinician.

Introduction (including agreed off-label usage) (updated Feb 2019)

Section 1 – Treatment of Depression (updated July 2017)
Section 2 – Treatment of Psychosis  (updated June 2019)
Section 3 – Treatment of Bipolar Affective Disorder   (updated June 2019)
Section 4 – Treatment of Anxiety (updated April 2019)
Section 5 – Treatment of Insomnia (updated June 2019)
Section 6 – Treatment of ADHD  (updated Sep 2018)
Section 7 – Management of Dementia (updated Dec 2018)
Section 8 – Treatment of Acutely Disturbed Behaviour (updated Feb 2019)
Section 9 – Treatment of Movement Disorders (updated Nov 2017)
Section 10 – Management of Alcohol, Opioid and Benzodiazepine Dependence (updated June 2018)
Section 11 – Drug Use in Older Adults (updated June 2019)
Section 12 – Drug Use in Children & Adolescents (updated June 2019)
Section 13 – Drug Use in Learning Disabilities (updated June 2019)
Section 14 – Anticoagulants (updated June 2018)
Section 15 – Treatment of Eating Disorders (updated Dec 2018)
Section 16 – Treatment of Anaphylaxis (updated Nov 2017)
Section 17 – Nicotine Replacement Therapy (updated July 2018)
Section 18 – Antimicrobial Prescribing (updated April 2019)
Section 19 – Treatment of Hypoglycaemia (updated Dec 2017)
Section 20 – Antenatal and Postnatal Prescribing (updated June 2019)
Section 21 – High Risk Medicines (new June 2019)

Protocol for supply of Nicotine Inhalator on admission (updated October 2017)
Protocol for the administration of Paracetamol (new September 2017)
Protocol for the administration of Peptac (new September 2017)
Protocol for the administration of Senna 9new September 2017)

Shared Care Protocol – Lithium

Shared Care Protocol – Melatonin

Shared Care Protocol –  Treatment of ADHD

Shared Care Protocol – Alzheimers Disease